Axsome Near Highs: Buying the Pullback Into a Defined FDA Clock
Axsome Therapeutics is pushing back toward its 52-week high as momentum stays bullish and the market leans into an April 2026 FDA decision for AXS-05 in Alzheimer’s agitation. The stock is not cheap on sales, but the setup is actionable: buy a controlled pullback with a tight stop, aiming for a retest and potential breakout of the $191.50 high. The…